FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078161887> ?p ?o ?g. }

• W2078161887 endingPage "1543" @default.
• W2078161887 startingPage "1541" @default.
• W2078161887 abstract "We report the case of a patient referred to us for mitral and aortic valvular disease with a rheumatic appearance. The unusual macroscopic appearance on valve resection was not compatible with a rheumatic cause. A detailed review of this patient’s clinical history (ie, a history of treatment with fenfluramine) suggested an iatrogenic cause, which was confirmed by histology. For the first time, a case of valvular heart disease that deteriorated was discovered 7 years after treatment with fenfluramine, whereas this iatrogenic disease classically resolves after discontinuation of treatment. This case illustrates the need for continuing heart valve surveillance of patients who have used these anorectics. We report the case of a patient referred to us for mitral and aortic valvular disease with a rheumatic appearance. The unusual macroscopic appearance on valve resection was not compatible with a rheumatic cause. A detailed review of this patient’s clinical history (ie, a history of treatment with fenfluramine) suggested an iatrogenic cause, which was confirmed by histology. For the first time, a case of valvular heart disease that deteriorated was discovered 7 years after treatment with fenfluramine, whereas this iatrogenic disease classically resolves after discontinuation of treatment. This case illustrates the need for continuing heart valve surveillance of patients who have used these anorectics. Fenfluramine, a serotonergic anorectic, was marketed in 1973 and then later withdrawn from the market on September 15, 1997 due to the risk of development of primary pulmonary hypertension or valvular heart disease. The authors report the first case of fenfluramine-associated valvular heart disease discovered 7 years after discontinuation of treatment and requiring double valve replacement 2 years later.A 39-year-old woman was hospitalized for management of pneumonia. A systolodiastolic murmur detected at the age of 25 years was re-evaluated. She reported increasing breathlessness on exertion over the previous 2 years. Echocardiography showed grade III mitral incompetence (surface = 1.5 cm2) and grade II/III aortic incompetence with retractile lesions and a rheumatic appearance. These findings were confirmed by cardiac catheterization. This patient did not present any risk factors or any history of rheumatic disease.Therefore the patient was operated on for a double mechanical valve replacement. The macroscopic appearance was very unusual, with a pearly white and retractile appearance of the mitral and aortic cusps (Fig 1, Fig 2), with no commissural symphysis or calcification. The mitral subvalvular apparatus was thickened and retractile.Fig 2Macroscopic appearance: anterior leaflet of the mitral valve with thickened and retractile insertion of the chordae tendineae.View Large Image Figure ViewerDownload (PPT)A detailed review of this patient’s clinical history revealed anorexia nervosa after a first pregnancy at the age of 19 (106 kg postpartum). No heart murmur was detected at that time. She then started intermittent treatment with serotoninergic anorectics for a period of 10 years (with a complete first year and then 2 months per year for a cumulative total of 34 months of fenfluramine [60 mg/day] and 3 months of dexfenfluramine [45 mg/day]). The patient’s murmur was discovered at the age of 25 years (ie, 6 years after she was started on anorectics) by an occupational health physician, and the patient remained moderate during a second pregnancy without any problems at the age of 27 years.Histologic examination did not show any vessels with thickened walls as observed in rheumatic lesions. The aortic valve was thickened with proliferation of spindle-shaped cells (Fig 3), corresponding to myofibroblasts expressing smooth muscle α-actin (Fig 4). The valve surface was intact with no vegetations and no signs of myxoid degeneration or calcification.Fig 3Proliferation of myofibroblasts in the superior part (×20).View Large Image Figure ViewerDownload (PPT)Fig 4Labelling of myofibroblasts by anti-smooth muscle α-actin antibody.View Large Image Figure ViewerDownload (PPT)Overall, the clinical history, the macroscopic appearance, and the histology indicated a diagnosis of fenfluramine-induced valvular heart disease.CommentEpidemiologyAn estimated 70 million patients worldwide took fenfluramine between 1973 and 1997. In 1996, the total number of prescriptions of fenfluramine in the United States exceeded 18 million [1Langreth R. Critics claim diet clinics misuse obesity drugs.Wall Street Journal. 1997; (March 31): B8Google Scholar].In industrialized countries, it has been estimated that almost 1 in 1,200 inhabitants has consumed fenfluramine for at least 3 months. The incidences of valvular heart diseases are fivefold higher when the duration of treatments exceeds 4 months [2Jick H. Vasilakis C. Weinrauch L.A. Meier C.R. Jick S.S. Derby L.E. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation.N Engl J Med. 1998; 339: 719-724Crossref PubMed Scopus (225) Google Scholar], which was the case with our patient who took treatments for 37 months. The risks of fenfluramine were defined in 1997 as 1 of 25,000 for the development of pulmonary hypertension (20% of all cases of primary pulmonary hypertension) with disabling respiratory consequences. The risk of valvular heart disease is 20% with fenfluramine and 12.5% with dexfenfluramine, but with only minor consequences rarely leading to valve replacement. A meta-analysis concerning 1,279 patients in 2002 revealed 18% of aortic incompetence (risk ratio [RR], 2.32) and 5% of mitral incompetence (RR, 1.55) [3Loke Y.K. Derry S. Pritchard-Copley A. Appetite suppressants and valvular heart disease—a systematic review.BMC Clin Pharmacol. 2002; 2: 6Crossref PubMed Scopus (42) Google Scholar], essentially consisting of moderate regurgitation requiring surgery in only 9% of cases. Echocardiographic follow-up after discontinuation of fenfluramine showed stabilization or even improvement of the severity of regurgitation [4Mast S.T. Jollis J.G. Ryan T. Anstrom K.J. Crary J.L. The progression of fenfluramine-associated valvular heart disease assessed by echocardiography.Ann Intern Med. 2001; 134: 261-266Crossref PubMed Scopus (58) Google Scholar], whereas in our case the murmur and the symptoms appeared a long time after stopping treatment (Fig 5). There is a published case [5Prasad A. Mehra M. Park M. Scott R. Uber P.A. McFadden P.M. Cardiac allograft valvulopathy: a case of donor-anorexigen-induced valvular disease.Ann Thorac Surg. 2001; 71: 397Google Scholar] describing a heart transplant recipient in whom the donor had taken fenfluramine. The transplant recipient had never taken any anorectics, but his pre-existing valvular heart disease nevertheless deteriorated after transplantation.Fig 5Chronology of onset of valvular heart disease after fenfluramine therapy.View Large Image Figure ViewerDownload (PPT)Echocardiographic AppearanceThe consequences of a retracted, reorganized, and fibrous mitral subvalvular apparatus (ie, valves that remain relatively flexible and noncalcified and are essentially regurgitating) are suggestive of valvular heart disease associated with fenfluramine [6Caccitolo J.A. Connolly H.M. Rubenson D.S. Orszulak T.A. Schaff H.V. Operation for anorexigen-associated valvular heart disease.JTCS. 2001; 122: 656-664PubMed Google Scholar, 7Connolly H.M. Crary J.L. McGoon M.D. Valvular heart disease associated with fenfluramine-phentermine.N Engl J Med. 1997; 337: 581-588Crossref PubMed Scopus (1380) Google Scholar].Histopathologic AppearanceThe macroscopic appearance corresponds to that reported in valvular heart disease associated with fenfluramine [6Caccitolo J.A. Connolly H.M. Rubenson D.S. Orszulak T.A. Schaff H.V. Operation for anorexigen-associated valvular heart disease.JTCS. 2001; 122: 656-664PubMed Google Scholar, 7Connolly H.M. Crary J.L. McGoon M.D. Valvular heart disease associated with fenfluramine-phentermine.N Engl J Med. 1997; 337: 581-588Crossref PubMed Scopus (1380) Google Scholar, 8Steffee C.H. Singh H.K. Chitwood W.R. Histologic changes in three explanted native cardiac valves following use of fenfluramines.Cardiovasc Pathol. 1999; 8: 245-253Abstract Full Text Full Text PDF PubMed Scopus (31) Google Scholar] with a typical proliferative appearance of the myofibroblasts during the acute intoxication phase. This typical proliferation was observed in our patient, but to a lesser degree, probably due to the longer interval after discontinuation of treatment. Fenfluramine appears to activate myofibroblast proliferation through a 5HT-2B receptor, which could be perpetuated by endogenous serotonin [9Volmar K.E. Hutchins G.M. Aortic and mitral fenfluramine-phentermine valvulopathy in 64 patients treated with anorectic agents.Arch Pathol Lab Med. 2001; 125: 1555-1561PubMed Google Scholar].Public HealthProphylaxis of bacterial endocarditis in patients who have taken oral anorectics is recommended [10Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U. S. Department of Health and Human Services interim public health recommendations, November 1997.MMWR Morb Mortal Wkly Rep. 1997; 46: 1061-1066PubMed Google Scholar].In conclusion, this case suggests that severe regurgitating valvular heart disease associated with fenfluramine can occur late. This case may be exceptional as it occurred after taking high doses of anorectics for a long time. However, in view of the number of exposed patients, increased health surveillance should be recommended to more clearly determine this risk. Fenfluramine, a serotonergic anorectic, was marketed in 1973 and then later withdrawn from the market on September 15, 1997 due to the risk of development of primary pulmonary hypertension or valvular heart disease. The authors report the first case of fenfluramine-associated valvular heart disease discovered 7 years after discontinuation of treatment and requiring double valve replacement 2 years later. A 39-year-old woman was hospitalized for management of pneumonia. A systolodiastolic murmur detected at the age of 25 years was re-evaluated. She reported increasing breathlessness on exertion over the previous 2 years. Echocardiography showed grade III mitral incompetence (surface = 1.5 cm2) and grade II/III aortic incompetence with retractile lesions and a rheumatic appearance. These findings were confirmed by cardiac catheterization. This patient did not present any risk factors or any history of rheumatic disease. Therefore the patient was operated on for a double mechanical valve replacement. The macroscopic appearance was very unusual, with a pearly white and retractile appearance of the mitral and aortic cusps (Fig 1, Fig 2), with no commissural symphysis or calcification. The mitral subvalvular apparatus was thickened and retractile. A detailed review of this patient’s clinical history revealed anorexia nervosa after a first pregnancy at the age of 19 (106 kg postpartum). No heart murmur was detected at that time. She then started intermittent treatment with serotoninergic anorectics for a period of 10 years (with a complete first year and then 2 months per year for a cumulative total of 34 months of fenfluramine [60 mg/day] and 3 months of dexfenfluramine [45 mg/day]). The patient’s murmur was discovered at the age of 25 years (ie, 6 years after she was started on anorectics) by an occupational health physician, and the patient remained moderate during a second pregnancy without any problems at the age of 27 years. Histologic examination did not show any vessels with thickened walls as observed in rheumatic lesions. The aortic valve was thickened with proliferation of spindle-shaped cells (Fig 3), corresponding to myofibroblasts expressing smooth muscle α-actin (Fig 4). The valve surface was intact with no vegetations and no signs of myxoid degeneration or calcification. Overall, the clinical history, the macroscopic appearance, and the histology indicated a diagnosis of fenfluramine-induced valvular heart disease. CommentEpidemiologyAn estimated 70 million patients worldwide took fenfluramine between 1973 and 1997. In 1996, the total number of prescriptions of fenfluramine in the United States exceeded 18 million [1Langreth R. Critics claim diet clinics misuse obesity drugs.Wall Street Journal. 1997; (March 31): B8Google Scholar].In industrialized countries, it has been estimated that almost 1 in 1,200 inhabitants has consumed fenfluramine for at least 3 months. The incidences of valvular heart diseases are fivefold higher when the duration of treatments exceeds 4 months [2Jick H. Vasilakis C. Weinrauch L.A. Meier C.R. Jick S.S. Derby L.E. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation.N Engl J Med. 1998; 339: 719-724Crossref PubMed Scopus (225) Google Scholar], which was the case with our patient who took treatments for 37 months. The risks of fenfluramine were defined in 1997 as 1 of 25,000 for the development of pulmonary hypertension (20% of all cases of primary pulmonary hypertension) with disabling respiratory consequences. The risk of valvular heart disease is 20% with fenfluramine and 12.5% with dexfenfluramine, but with only minor consequences rarely leading to valve replacement. A meta-analysis concerning 1,279 patients in 2002 revealed 18% of aortic incompetence (risk ratio [RR], 2.32) and 5% of mitral incompetence (RR, 1.55) [3Loke Y.K. Derry S. Pritchard-Copley A. Appetite suppressants and valvular heart disease—a systematic review.BMC Clin Pharmacol. 2002; 2: 6Crossref PubMed Scopus (42) Google Scholar], essentially consisting of moderate regurgitation requiring surgery in only 9% of cases. Echocardiographic follow-up after discontinuation of fenfluramine showed stabilization or even improvement of the severity of regurgitation [4Mast S.T. Jollis J.G. Ryan T. Anstrom K.J. Crary J.L. The progression of fenfluramine-associated valvular heart disease assessed by echocardiography.Ann Intern Med. 2001; 134: 261-266Crossref PubMed Scopus (58) Google Scholar], whereas in our case the murmur and the symptoms appeared a long time after stopping treatment (Fig 5). There is a published case [5Prasad A. Mehra M. Park M. Scott R. Uber P.A. McFadden P.M. Cardiac allograft valvulopathy: a case of donor-anorexigen-induced valvular disease.Ann Thorac Surg. 2001; 71: 397Google Scholar] describing a heart transplant recipient in whom the donor had taken fenfluramine. The transplant recipient had never taken any anorectics, but his pre-existing valvular heart disease nevertheless deteriorated after transplantation.Echocardiographic AppearanceThe consequences of a retracted, reorganized, and fibrous mitral subvalvular apparatus (ie, valves that remain relatively flexible and noncalcified and are essentially regurgitating) are suggestive of valvular heart disease associated with fenfluramine [6Caccitolo J.A. Connolly H.M. Rubenson D.S. Orszulak T.A. Schaff H.V. Operation for anorexigen-associated valvular heart disease.JTCS. 2001; 122: 656-664PubMed Google Scholar, 7Connolly H.M. Crary J.L. McGoon M.D. Valvular heart disease associated with fenfluramine-phentermine.N Engl J Med. 1997; 337: 581-588Crossref PubMed Scopus (1380) Google Scholar].Histopathologic AppearanceThe macroscopic appearance corresponds to that reported in valvular heart disease associated with fenfluramine [6Caccitolo J.A. Connolly H.M. Rubenson D.S. Orszulak T.A. Schaff H.V. Operation for anorexigen-associated valvular heart disease.JTCS. 2001; 122: 656-664PubMed Google Scholar, 7Connolly H.M. Crary J.L. McGoon M.D. Valvular heart disease associated with fenfluramine-phentermine.N Engl J Med. 1997; 337: 581-588Crossref PubMed Scopus (1380) Google Scholar, 8Steffee C.H. Singh H.K. Chitwood W.R. Histologic changes in three explanted native cardiac valves following use of fenfluramines.Cardiovasc Pathol. 1999; 8: 245-253Abstract Full Text Full Text PDF PubMed Scopus (31) Google Scholar] with a typical proliferative appearance of the myofibroblasts during the acute intoxication phase. This typical proliferation was observed in our patient, but to a lesser degree, probably due to the longer interval after discontinuation of treatment. Fenfluramine appears to activate myofibroblast proliferation through a 5HT-2B receptor, which could be perpetuated by endogenous serotonin [9Volmar K.E. Hutchins G.M. Aortic and mitral fenfluramine-phentermine valvulopathy in 64 patients treated with anorectic agents.Arch Pathol Lab Med. 2001; 125: 1555-1561PubMed Google Scholar].Public HealthProphylaxis of bacterial endocarditis in patients who have taken oral anorectics is recommended [10Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U. S. Department of Health and Human Services interim public health recommendations, November 1997.MMWR Morb Mortal Wkly Rep. 1997; 46: 1061-1066PubMed Google Scholar].In conclusion, this case suggests that severe regurgitating valvular heart disease associated with fenfluramine can occur late. This case may be exceptional as it occurred after taking high doses of anorectics for a long time. However, in view of the number of exposed patients, increased health surveillance should be recommended to more clearly determine this risk. EpidemiologyAn estimated 70 million patients worldwide took fenfluramine between 1973 and 1997. In 1996, the total number of prescriptions of fenfluramine in the United States exceeded 18 million [1Langreth R. Critics claim diet clinics misuse obesity drugs.Wall Street Journal. 1997; (March 31): B8Google Scholar].In industrialized countries, it has been estimated that almost 1 in 1,200 inhabitants has consumed fenfluramine for at least 3 months. The incidences of valvular heart diseases are fivefold higher when the duration of treatments exceeds 4 months [2Jick H. Vasilakis C. Weinrauch L.A. Meier C.R. Jick S.S. Derby L.E. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation.N Engl J Med. 1998; 339: 719-724Crossref PubMed Scopus (225) Google Scholar], which was the case with our patient who took treatments for 37 months. The risks of fenfluramine were defined in 1997 as 1 of 25,000 for the development of pulmonary hypertension (20% of all cases of primary pulmonary hypertension) with disabling respiratory consequences. The risk of valvular heart disease is 20% with fenfluramine and 12.5% with dexfenfluramine, but with only minor consequences rarely leading to valve replacement. A meta-analysis concerning 1,279 patients in 2002 revealed 18% of aortic incompetence (risk ratio [RR], 2.32) and 5% of mitral incompetence (RR, 1.55) [3Loke Y.K. Derry S. Pritchard-Copley A. Appetite suppressants and valvular heart disease—a systematic review.BMC Clin Pharmacol. 2002; 2: 6Crossref PubMed Scopus (42) Google Scholar], essentially consisting of moderate regurgitation requiring surgery in only 9% of cases. Echocardiographic follow-up after discontinuation of fenfluramine showed stabilization or even improvement of the severity of regurgitation [4Mast S.T. Jollis J.G. Ryan T. Anstrom K.J. Crary J.L. The progression of fenfluramine-associated valvular heart disease assessed by echocardiography.Ann Intern Med. 2001; 134: 261-266Crossref PubMed Scopus (58) Google Scholar], whereas in our case the murmur and the symptoms appeared a long time after stopping treatment (Fig 5). There is a published case [5Prasad A. Mehra M. Park M. Scott R. Uber P.A. McFadden P.M. Cardiac allograft valvulopathy: a case of donor-anorexigen-induced valvular disease.Ann Thorac Surg. 2001; 71: 397Google Scholar] describing a heart transplant recipient in whom the donor had taken fenfluramine. The transplant recipient had never taken any anorectics, but his pre-existing valvular heart disease nevertheless deteriorated after transplantation. An estimated 70 million patients worldwide took fenfluramine between 1973 and 1997. In 1996, the total number of prescriptions of fenfluramine in the United States exceeded 18 million [1Langreth R. Critics claim diet clinics misuse obesity drugs.Wall Street Journal. 1997; (March 31): B8Google Scholar]. In industrialized countries, it has been estimated that almost 1 in 1,200 inhabitants has consumed fenfluramine for at least 3 months. The incidences of valvular heart diseases are fivefold higher when the duration of treatments exceeds 4 months [2Jick H. Vasilakis C. Weinrauch L.A. Meier C.R. Jick S.S. Derby L.E. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation.N Engl J Med. 1998; 339: 719-724Crossref PubMed Scopus (225) Google Scholar], which was the case with our patient who took treatments for 37 months. The risks of fenfluramine were defined in 1997 as 1 of 25,000 for the development of pulmonary hypertension (20% of all cases of primary pulmonary hypertension) with disabling respiratory consequences. The risk of valvular heart disease is 20% with fenfluramine and 12.5% with dexfenfluramine, but with only minor consequences rarely leading to valve replacement. A meta-analysis concerning 1,279 patients in 2002 revealed 18% of aortic incompetence (risk ratio [RR], 2.32) and 5% of mitral incompetence (RR, 1.55) [3Loke Y.K. Derry S. Pritchard-Copley A. Appetite suppressants and valvular heart disease—a systematic review.BMC Clin Pharmacol. 2002; 2: 6Crossref PubMed Scopus (42) Google Scholar], essentially consisting of moderate regurgitation requiring surgery in only 9% of cases. Echocardiographic follow-up after discontinuation of fenfluramine showed stabilization or even improvement of the severity of regurgitation [4Mast S.T. Jollis J.G. Ryan T. Anstrom K.J. Crary J.L. The progression of fenfluramine-associated valvular heart disease assessed by echocardiography.Ann Intern Med. 2001; 134: 261-266Crossref PubMed Scopus (58) Google Scholar], whereas in our case the murmur and the symptoms appeared a long time after stopping treatment (Fig 5). There is a published case [5Prasad A. Mehra M. Park M. Scott R. Uber P.A. McFadden P.M. Cardiac allograft valvulopathy: a case of donor-anorexigen-induced valvular disease.Ann Thorac Surg. 2001; 71: 397Google Scholar] describing a heart transplant recipient in whom the donor had taken fenfluramine. The transplant recipient had never taken any anorectics, but his pre-existing valvular heart disease nevertheless deteriorated after transplantation. Echocardiographic AppearanceThe consequences of a retracted, reorganized, and fibrous mitral subvalvular apparatus (ie, valves that remain relatively flexible and noncalcified and are essentially regurgitating) are suggestive of valvular heart disease associated with fenfluramine [6Caccitolo J.A. Connolly H.M. Rubenson D.S. Orszulak T.A. Schaff H.V. Operation for anorexigen-associated valvular heart disease.JTCS. 2001; 122: 656-664PubMed Google Scholar, 7Connolly H.M. Crary J.L. McGoon M.D. Valvular heart disease associated with fenfluramine-phentermine.N Engl J Med. 1997; 337: 581-588Crossref PubMed Scopus (1380) Google Scholar]. The consequences of a retracted, reorganized, and fibrous mitral subvalvular apparatus (ie, valves that remain relatively flexible and noncalcified and are essentially regurgitating) are suggestive of valvular heart disease associated with fenfluramine [6Caccitolo J.A. Connolly H.M. Rubenson D.S. Orszulak T.A. Schaff H.V. Operation for anorexigen-associated valvular heart disease.JTCS. 2001; 122: 656-664PubMed Google Scholar, 7Connolly H.M. Crary J.L. McGoon M.D. Valvular heart disease associated with fenfluramine-phentermine.N Engl J Med. 1997; 337: 581-588Crossref PubMed Scopus (1380) Google Scholar]. Histopathologic AppearanceThe macroscopic appearance corresponds to that reported in valvular heart disease associated with fenfluramine [6Caccitolo J.A. Connolly H.M. Rubenson D.S. Orszulak T.A. Schaff H.V. Operation for anorexigen-associated valvular heart disease.JTCS. 2001; 122: 656-664PubMed Google Scholar, 7Connolly H.M. Crary J.L. McGoon M.D. Valvular heart disease associated with fenfluramine-phentermine.N Engl J Med. 1997; 337: 581-588Crossref PubMed Scopus (1380) Google Scholar, 8Steffee C.H. Singh H.K. Chitwood W.R. Histologic changes in three explanted native cardiac valves following use of fenfluramines.Cardiovasc Pathol. 1999; 8: 245-253Abstract Full Text Full Text PDF PubMed Scopus (31) Google Scholar] with a typical proliferative appearance of the myofibroblasts during the acute intoxication phase. This typical proliferation was observed in our patient, but to a lesser degree, probably due to the longer interval after discontinuation of treatment. Fenfluramine appears to activate myofibroblast proliferation through a 5HT-2B receptor, which could be perpetuated by endogenous serotonin [9Volmar K.E. Hutchins G.M. Aortic and mitral fenfluramine-phentermine valvulopathy in 64 patients treated with anorectic agents.Arch Pathol Lab Med. 2001; 125: 1555-1561PubMed Google Scholar]. The macroscopic appearance corresponds to that reported in valvular heart disease associated with fenfluramine [6Caccitolo J.A. Connolly H.M. Rubenson D.S. Orszulak T.A. Schaff H.V. Operation for anorexigen-associated valvular heart disease.JTCS. 2001; 122: 656-664PubMed Google Scholar, 7Connolly H.M. Crary J.L. McGoon M.D. Valvular heart disease associated with fenfluramine-phentermine.N Engl J Med. 1997; 337: 581-588Crossref PubMed Scopus (1380) Google Scholar, 8Steffee C.H. Singh H.K. Chitwood W.R. Histologic changes in three explanted native cardiac valves following use of fenfluramines.Cardiovasc Pathol. 1999; 8: 245-253Abstract Full Text Full Text PDF PubMed Scopus (31) Google Scholar] with a typical proliferative appearance of the myofibroblasts during the acute intoxication phase. This typical proliferation was observed in our patient, but to a lesser degree, probably due to the longer interval after discontinuation of treatment. Fenfluramine appears to activate myofibroblast proliferation through a 5HT-2B receptor, which could be perpetuated by endogenous serotonin [9Volmar K.E. Hutchins G.M. Aortic and mitral fenfluramine-phentermine valvulopathy in 64 patients treated with anorectic agents.Arch Pathol Lab Med. 2001; 125: 1555-1561PubMed Google Scholar]. Public HealthProphylaxis of bacterial endocarditis in patients who have taken oral anorectics is recommended [10Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U. S. Department of Health and Human Services interim public health recommendations, November 1997.MMWR Morb Mortal Wkly Rep. 1997; 46: 1061-1066PubMed Google Scholar].In conclusion, this case suggests that severe regurgitating valvular heart disease associated with fenfluramine can occur late. This case may be exceptional as it occurred after taking high doses of anorectics for a long time. However, in view of the number of exposed patients, increased health surveillance should be recommended to more clearly determine this risk. Prophylaxis of bacterial endocarditis in patients who have taken oral anorectics is recommended [10Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U. S. Department of Health and Human Services interim public health recommendations, November 1997.MMWR Morb Mortal Wkly Rep. 1997; 46: 1061-1066PubMed Google Scholar]. In conclusion, this case suggests that severe regurgitating valvular heart disease associated with fenfluramine can occur late. This case may be exceptional as it occurred after taking high doses of anorectics for a long time. However, in view of the number of exposed patients, increased health surveillance should be recommended to more clearly determine this risk." @default.
• W2078161887 created "2016-06-24" @default.
• W2078161887 creator A5004379451 @default.
• W2078161887 creator A5013729395 @default.
• W2078161887 creator A5027158494 @default.
• W2078161887 creator A5032413483 @default.
• W2078161887 creator A5050013841 @default.
• W2078161887 creator A5077440129 @default.
• W2078161887 creator A5081194970 @default.
• W2078161887 date "2007-04-01" @default.
• W2078161887 modified "2023-09-23" @default.
• W2078161887 title "Valvular Heart Disease Associated With Fenfluramine Detected 7 Years After Discontinuation of Treatment" @default.
• W2078161887 cites W1962299285 @default.
• W2078161887 cites W1971110437 @default.
• W2078161887 cites W1973991738 @default.
• W2078161887 cites W2021332243 @default.
• W2078161887 cites W2134362869 @default.
• W2078161887 cites W4230755824 @default.
• W2078161887 doi "https://doi.org/10.1016/j.athoracsur.2006.11.031" @default.
• W2078161887 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17383382" @default.
• W2078161887 hasPublicationYear "2007" @default.
• W2078161887 type Work @default.
• W2078161887 sameAs 2078161887 @default.
• W2078161887 citedByCount "14" @default.
• W2078161887 countsByYear W20781618872012 @default.
• W2078161887 countsByYear W20781618872013 @default.
• W2078161887 countsByYear W20781618872014 @default.
• W2078161887 countsByYear W20781618872015 @default.
• W2078161887 countsByYear W20781618872016 @default.
• W2078161887 countsByYear W20781618872021 @default.
• W2078161887 countsByYear W20781618872023 @default.
• W2078161887 crossrefType "journal-article" @default.
• W2078161887 hasAuthorship W2078161887A5004379451 @default.
• W2078161887 hasAuthorship W2078161887A5013729395 @default.
• W2078161887 hasAuthorship W2078161887A5027158494 @default.
• W2078161887 hasAuthorship W2078161887A5032413483 @default.
• W2078161887 hasAuthorship W2078161887A5050013841 @default.
• W2078161887 hasAuthorship W2078161887A5077440129 @default.
• W2078161887 hasAuthorship W2078161887A5081194970 @default.
• W2078161887 hasBestOaLocation W20781618871 @default.
• W2078161887 hasConcept C126322002 @default.
• W2078161887 hasConcept C141071460 @default.
• W2078161887 hasConcept C164705383 @default.
• W2078161887 hasConcept C170493617 @default.
• W2078161887 hasConcept C2775864247 @default.
• W2078161887 hasConcept C2778715236 @default.
• W2078161887 hasConcept C2779638493 @default.
• W2078161887 hasConcept C2779736815 @default.
• W2078161887 hasConcept C2780074459 @default.
• W2078161887 hasConcept C71924100 @default.
• W2078161887 hasConceptScore W2078161887C126322002 @default.
• W2078161887 hasConceptScore W2078161887C141071460 @default.
• W2078161887 hasConceptScore W2078161887C164705383 @default.
• W2078161887 hasConceptScore W2078161887C170493617 @default.
• W2078161887 hasConceptScore W2078161887C2775864247 @default.
• W2078161887 hasConceptScore W2078161887C2778715236 @default.
• W2078161887 hasConceptScore W2078161887C2779638493 @default.
• W2078161887 hasConceptScore W2078161887C2779736815 @default.
• W2078161887 hasConceptScore W2078161887C2780074459 @default.
• W2078161887 hasConceptScore W2078161887C71924100 @default.
• W2078161887 hasIssue "4" @default.
• W2078161887 hasLocation W20781618871 @default.
• W2078161887 hasLocation W20781618872 @default.
• W2078161887 hasOpenAccess W2078161887 @default.
• W2078161887 hasPrimaryLocation W20781618871 @default.
• W2078161887 hasRelatedWork W2003938723 @default.
• W2078161887 hasRelatedWork W2012358447 @default.
• W2078161887 hasRelatedWork W2047967234 @default.
• W2078161887 hasRelatedWork W2078161887 @default.
• W2078161887 hasRelatedWork W2118496982 @default.
• W2078161887 hasRelatedWork W2439875401 @default.
• W2078161887 hasRelatedWork W2443687130 @default.
• W2078161887 hasRelatedWork W2466043692 @default.
• W2078161887 hasRelatedWork W4238867864 @default.
• W2078161887 hasRelatedWork W2525756941 @default.
• W2078161887 hasVolume "83" @default.
• W2078161887 isParatext "false" @default.
• W2078161887 isRetracted "false" @default.
• W2078161887 magId "2078161887" @default.
• W2078161887 workType "article" @default.